| Literature DB >> 31782369 |
Juan A Siordia1, Jimena C Franco2.
Abstract
OBJECTIVE: The debate pertaining to the association between Keratoconus (KC) and Mitral Valve Prolapse (MVP) continues to occur among physicians. The results of cross-sectional studies attempting to present the co-existing prevalence of these two diseases remain indeterminate. We compiled the first meta-analysis to determine the pattern of prevalence between the two diseases.Entities:
Keywords: Keratoconus; association; cardiology; epidemiology; mitral valve prolapse; ophthalmology.
Mesh:
Year: 2020 PMID: 31782369 PMCID: PMC7460702 DOI: 10.2174/1573403X15666191129100928
Source DB: PubMed Journal: Curr Cardiol Rev ISSN: 1573-403X
Details of selected studies.
|
|
|
|
|
|
|---|---|---|---|---|
| Akcay | KC in patients with MVP | 97 (MVP = 52; Control = 45) | KC in MVP = 5.7%; KC in Control = 1.1% (p = 0.25) | Mention a group of patients with suspected KC, but only the definite KC patients were used in our meta-analysis. |
| Lichter | KC in patients with MVP | 61 (MVP = 36; Control = 25) | KC in MVP = 22.2%; KC in Control = 4.0% (p = 0.08) | - |
| Rabbanikhah | MVP in patients with KC | 160 (KC = 32; Control = 128) | MVP in KC = 65.6%; MVP in Control = 9.0% (p < 0.01) | The patients with KC also had acute corneal hydrops while the patients in the control group had no ophthalmic diseases. |
| Javadi | MVP in patients with KC | 229 (KC = 62; Control = 167) | MVP in KC = 22.6%; MVP in Control = 6.6% (p < 0.01) | The odds ratio for MVP increased with each decade (lower than third decade, third decade, and fourth decade and above noted). |
| Mohammady | MVP in patients with KC | 60 (KC = 30; Control = 30) | MVP in KC = 90.0%; MVP in Control = 40.0% (p < 0.01) | - |
| Sharif | MVP in patients with KC | 100 (KC = 50; Control = 50) | MVP in KC = 58.0%; MVP in Control = 7.0% (p < 0.01) | - |
| Street | MVP in patients with KC | 191 (KC = 95; Control = 96) | MVP in KC = 21.1%; MVP in Control = 17.7% (p = 0.56) | - |
| Beardsely | MVP in patients with KC | 45 (KC = 22; Control = 23) | MVP in KC = 40.9%; MVP in Control = 13.0% (p = 0.04) | - |
Abbreviations: KC = Keratoconus; MVP = Mitral Valve Prolapse.
Baseline characteristics of combined studies.
|
|
|
| ||
|---|---|---|---|---|
|
|
|
|
| |
| Age [mean (range)] | 29 (17-64) | 29.8 (15-65) | 44.5 (19-79) | 41.1 (20-78) |
| Gender [total male/ total female] | 164/95 | 269/137 | 44/44 | 36/34 |
| Total patients | 291 | 494 | 88 | 70 |
Abbreviations: MVP = mitral valve prolapse; KC = keratoconus.
Contributions to baseline characteristics.
|
|
|
|---|---|
| Akcay | Age, Gender, Total (KC in MVP patients) |
| Lichter | Age, Gender, Total (KC in MVP patients) |
| Rabbanikhah | Age, Gender, Total (MVP in KC patients) |
| Javadi | Age, Gender, Total (MVP in KC patients) |
| Mohammady | Total (MVP in KC patients) |
| Sharif | Age and Gender only of patients in study group, Total (MVP in KC patients) |
| Street | Gender, Total (MVP in KC patients) |
| Beardsely | Age, Gender, Total (MVP in KC patients) |
Abbreviations: KC = Keratoconus; MVP = Mitral Valve Prolapse.